Lifecycle of an Imaging Biomarker

Lifecycle of an Imaging Biomarker: From Validation to Dissemination

Thursday, Dec. 2, 10:30 AM - 12:00 PM

Speakers are sharing perspectives on the use of quantitative imaging as a biomarker in clinical trials and providing examples of best practices.

The speakers are:
  • Jeffrey T. Yap, PhD, senior diagnostic physicist, Dana-Farber Cancer Institute in Boston;
  • Neil M. Rofsky, MD, chief, MRI, Beth Israel Deaconess Medical Center in Boston;
  • Simon K. Warfield, PhD, director, computational radiology laboratory, Children’s Hospital in Boston.

Around the web

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services.